TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01622569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Delivered via Optinose Exhalation Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Delivered via Optinose Exhalation Delivery System
Study: NCT00855738

Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide
Description: * Gabapentin: up to 3.600 mg/d~* Lamotrigine: up to 400 mg/d~* Levetiracetam: up to 3.000 mg/d~* Pregabalin: up to 600 mg/d~* Oxcarbazepine: up to 2.400 mg/d~* Tiagabine: up to 30 mg/d~* Topiramate: up to 400 mg/d~* Zonisamide: up to 500 mg/d
Study: NCT00796926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Ultra eyedrops
Description: Four times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh eye drops
Description: Four times a day
Study: NCT04511377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation using Digital Healthcare System (Uincare Homeplus)
Description: Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Home-based self-rehabilitation using brochure for 12 weeks post surgery.
Study: NCT02065388

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care dosing for warfarin

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosingTaiwan algorithm for warfarin

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing IWPC algorithm for warfarin
Study: NCT02748382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: higher chloride crystalloid
Description: Normal saline
Study: NCT01622569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Delivered via Optinose Exhalation Delivery System

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: Delivered via Optinose Exhalation Delivery System
Study: NCT00394849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture one tonsillar fossa
Description: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
Study: NCT00483860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: once a day
Study: NCT06528470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Tibial Nerve Stimulation (PTNS)
Description: The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when direct motor stimulation ceases and sensory stimulation is comfortable. Continuous stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when no stimulation is delivered. No stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
Study: NCT02374866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closer monitoring
Study: NCT03015467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
Study: NCT04381208

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete clinical examination
Description: Medical history-taking, physical examination with provocative maneuvers, radiographic imaging (if relevant), and sacroiliac joint block (if indicated), facet joint block (if indicated)

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete clinical examination
Description: Medical history-taking, physical examination with provocative maneuvers, radiographic imaging (if relevant), and sacroiliac joint block (if indicated), facet joint block (if indicated)
Study: NCT02141893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CALMA plus
Description: Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALMA plus
Description: Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CALMA
Description: Family Education Intervention on management of pediatric asthma
Study: NCT00524056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: two 100 mg tablets twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two placebo tablets twice per day
Study: NCT01833130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (placebo)
Description: Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
Study: NCT02507011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: Beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03257787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: new adhesive strip
Description: This is a strip made of a newly developed adhesive
Study: NCT01526109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training group
Description: Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training group
Description: Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
Study: NCT03054610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason Sodium Phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Study: NCT01441063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGC)
Description: Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
Study: NCT00704964

Intervention type: BIOLOGICAL
Intervention: PegIntron
Description: PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany

Intervention type: DRUG
Intervention: Rebetol
Description: Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
Study: NCT02748382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: higher chloride albumin
Description: 5% Octalbin
Study: NCT03634800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240mg
Description: Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.
Study: NCT03313674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
Study: NCT01491256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-procedural High dose atorvastatin loading
Description: Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No pre-procedural high-dose atorvastatin loading
Description: atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
Study: NCT01625780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-layer block
Description: 0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-shot block
Description: 0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
Study: NCT00969215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis fractional carbon dioxide laser
Description: Laser resurfacing of a burn scar
Study: NCT01877564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT00553046

Intervention type: OTHER
Intervention: survey administration
Description: application of a family survey on last 3 months of life for their relatives under HMV
Study: NCT04607733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab Prefilled Syringe
Description: Administered SC by prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab Autoinjector
Description: Administered SC by autoinjector
Study: NCT02065739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
Study: NCT02508805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromultivit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirdalud

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirdalud
Study: NCT03661320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study: NCT03061266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health Education
Description: E-health education on shared care program will be established by different type's professionals including diabetes physicians, pharmacists, dietitians and diabetes health teacher.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine care on shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
Study: NCT00653237

Intervention type: DEVICE
Group type: OTHER
Intervention: I-gel and LMA Supreme: supraglottic airway devices
Description: Insertion of a supraglottic airway device
Study: NCT01979497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture with Adhesive Stripping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture with Adhesive Stripping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture without Adhesive Stripping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture without Adhesive Stripping
Study: NCT01361997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chlorhexidine in isopropyl alcohol
Description: When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Description: When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
Study: NCT03618108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Capsule
Description: doxycycline capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Capsule
Description: azithromycin capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin Oral Capsule
Description: rifabutin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule identical in size and form to doxycycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral capsule identical in size and form to azithromcyin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule identical in size and form to rifabutin
Study: NCT01538485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: weekly dose (based on 70IU KG body weight/day)
Study: NCT02748382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower chloride crystalloid
Description: Ringers Lactate
Study: NCT01631305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 3 mcg/kg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcium magnesia
Description: Placebo.
Study: NCT02748382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower chloride albumin
Description: 5% Plasbumin
Study: NCT05479630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition With a Heart (TWAH)
Description: TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
Study: NCT02086188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: see detailed information in associated Arm Description
Study: NCT03343015

Intervention type: PROCEDURE
Intervention: complete dentures
Description: therapy with maxilla and mandible dentures

Intervention type: PROCEDURE
Intervention: complete dentures
Description: therapy with maxilla and mandible dentures
Study: NCT01415635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention using
Description: The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital).
Study: NCT03402997

Intervention type: DIAGNOSTIC_TEST
Intervention: Resistivity measurement
Description: To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
Study: NCT03631823

Intervention type: OTHER
Intervention: Chemotherapy with temozolomide or no chemotherapy
Description: This study is just an observational study.
Study: NCT02086188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Mirabegron 25mg tablet.
Study: NCT03396523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral)
Study: NCT03396523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study: NCT04349735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of inhalation technique
Description: Assessment of inhalation technique by 3 methods in every patient
Study: NCT02307734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit Smoking for a Healthy Family
Description: The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout.
Study: NCT02896322

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation with cyberknife
Study: NCT01785862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 25 mg
Description: Lozenge, Oromucosal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lozenge matching V0498 lozenge, Oromucosal administration